Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1981 to 1995 of 8221 results

  1. LIVERFASt for diagnosing and staging liver injury and chronic liver disease, (MT783)

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  2. iQoro neuromuscular training device, (MT809)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  3. Spectra Optia for plasma exchange, (MT828)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  4. Electrosurgery (diathermy and coblation) for tonsillectomy, (IP324/2)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  5. Accuro handheld ultrasound device for locating intervertebral space for administration of spinal anaesthesia

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  6. CADScor system for ruling out coronary artery disease in people with symptoms of stable coronary artery disease (MT434

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  7. Differential Target Multiplexed Spinal Cord Stimulation (MT742)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  8. Durvalumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6445]

    Awaiting development Reference number: GID-TA11517 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207]

    In development Reference number: GID-TA11235 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Durvalumab in combination for untreated advanced ovarian, fallopian tube or primary peritoneal cancer before and after surgery [ID6254]

    Awaiting development Reference number: GID-TA11281 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Acalabrutinib for treating relapsed or refractory mantle cell lymphoma [ID6389]

    Awaiting development Reference number: GID-TA11470 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]

    In development Reference number: GID-TA10664 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077]

    Awaiting development Reference number: GID-TA10971 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment [ID6387]

    Awaiting development Reference number: GID-TA11438 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Elinzanetant for treating vasomotor symptoms associated with menopause [ID6359]

    Awaiting development Reference number: GID-TA11428 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development